相似文献
1
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia.
Haematologica. 2016 Jun;101(6):672-9. doi: 10.3324/haematol.2015.141796.
2
A review of the Wilms' tumor 1 gene (WT1) and its role in hematopoiesis and leukemia.
J Hematother Stem Cell Res. 2002 Aug;11(4):589-99. doi: 10.1089/15258160260194749.
3
The molecular pathogenesis of acute myeloid leukemia.
Crit Rev Oncol Hematol. 2005 Nov;56(2):195-221. doi: 10.1016/j.critrevonc.2004.10.012. Epub 2005 Oct 19.
4
Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
Hematology. 2014 Jul;19(5):267-74. doi: 10.1179/1607845413Y.0000000129. Epub 2013 Nov 25.
5
The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells.
FEBS Lett. 1997 Jun 2;409(1):41-5. doi: 10.1016/s0014-5793(97)00477-8.
6
Harnessing the potential of epigenetic therapies for childhood acute myeloid leukemia.
Exp Hematol. 2018 Jul;63:1-11. doi: 10.1016/j.exphem.2018.03.008. Epub 2018 Mar 30.
7
Long Non-Coding RNA and Acute Leukemia.
Int J Mol Sci. 2019 Feb 9;20(3):735. doi: 10.3390/ijms20030735.
8
Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism.
Biol Blood Marrow Transplant. 2012 Aug;18(8):1235-42. doi: 10.1016/j.bbmt.2012.01.012. Epub 2012 Jan 25.
9
Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia.
Haematologica. 2004 Aug;89(8):926-33.
10
Expression of the Wilms' tumor gene (WT1) in human leukemias.
Leukemia. 1992 May;6(5):405-9.
引用本文的文献
1
, , and Mutations in Pediatric Leukemias.
Cancers (Basel). 2025 Jul 23;17(15):2443. doi: 10.3390/cancers17152443.
2
The up-regulation of TGF-β1 by miRNA-132-3p/WT1 is involved in inducing leukemia cells to differentiate into macrophages.
PLoS One. 2025 May 6;20(5):e0306150. doi: 10.1371/journal.pone.0306150. eCollection 2025.
3
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype.
Cancers (Basel). 2025 Apr 3;17(7):1213. doi: 10.3390/cancers17071213.
4
BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism.
Cell Death Discov. 2025 Mar 26;11(1):120. doi: 10.1038/s41420-025-02375-2.
5
Landscape of TET2 Mutations: From Hematological Malignancies to Solid Tumors.
Cancer Med. 2025 Mar;14(6):e70792. doi: 10.1002/cam4.70792.
6
Biomolecular condensation of human IDRs initiates endogenous transcription via intrachromosomal looping or high-density promoter localization.
Nucleic Acids Res. 2025 Feb 8;53(4). doi: 10.1093/nar/gkaf056.
7
BH3 Mimetics Augment Cytotoxic T Cell Killing of Acute Myeloid Leukemia via Mitochondrial Apoptotic Mechanism.
Res Sq. 2024 Dec 9:rs.3.rs-5307127. doi: 10.21203/rs.3.rs-5307127/v1.
8
Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center.
Front Oncol. 2024 Dec 2;14:1498409. doi: 10.3389/fonc.2024.1498409. eCollection 2024.
9
Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapy.
Transl Oncol. 2025 Feb;52:102237. doi: 10.1016/j.tranon.2024.102237. Epub 2024 Dec 12.
10
Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2).
Int J Mol Sci. 2024 Oct 30;25(21):11646. doi: 10.3390/ijms252111646.
本文引用的文献
1
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
Am J Hematol. 2015 Jul;90(7):602-7. doi: 10.1002/ajh.24014. Epub 2015 May 3.
2
Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies.
Front Immunol. 2015 Feb 4;6:36. doi: 10.3389/fimmu.2015.00036. eCollection 2015.
3
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
Am J Hematol. 2015 May;90(5):E77-9. doi: 10.1002/ajh.23965. Epub 2015 Feb 27.
4
WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
Mol Cell. 2015 Feb 19;57(4):662-673. doi: 10.1016/j.molcel.2014.12.023. Epub 2015 Jan 15.
5
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
Cell Rep. 2014 Dec 11;9(5):1841-1855. doi: 10.1016/j.celrep.2014.11.004. Epub 2014 Dec 4.
6
Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition.
Blood. 2015 Jan 8;125(2):316-26. doi: 10.1182/blood-2014-03-566018. Epub 2014 Nov 14.
7
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Blood. 2014 Oct 23;124(17):2705-12. doi: 10.1182/blood-2014-06-582809. Epub 2014 Sep 15.
8
Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.
Sci Transl Med. 2013 Mar 13;5(176):176ra33. doi: 10.1126/scitranslmed.3005661.
9
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.
N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14.
10
Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
Oncologist. 2012;17(2):250-9. doi: 10.1634/theoncologist.2011-0240. Epub 2012 Jan 30.
Zotero 插件